Panbela Schedules Conference Call on August 11, 2021, to Report 2021 Second Quarter Financial Results

Rhea-AI Summary

Panbela Therapeutics (Nasdaq: PBLA) announced a conference call for August 11, 2021, at 4:30 PM ET to discuss its second quarter results ending June 30, 2021. The call will be accessible via telephone and online. The company is developing its proprietary drug, SBP-101, for treating metastatic pancreatic ductal adenocarcinoma, showing promise in clinical studies. Importantly, SBP-101 has demonstrated potential efficacy without exacerbating common chemotherapy side effects, supporting additional evaluation in clinical trials.

Positive

• SBP-101 shows potential tumor growth inhibition in metastatic pancreatic cancer patients.
• Clinical studies indicate SBP-101 does not worsen bone marrow suppression or peripheral neuropathy, common adverse chemotherapy events.
• The safety profile supports further evaluation of SBP-101 in randomized clinical trials.

Negative

• Recently observed serious visual adverse events in patients are under evaluation.
• Patients with a history of retinopathy are excluded from SBP-101 studies.

MINNEAPOLIS, July 28, 2021 (GLOBE NEWSWIRE) --   Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that it will host a conference call on August 11, 2021, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2021. 

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

Date: August 11, 2021 
Time: 4:30 PM Eastern Time 
Toll Free: 877-407-9205 
International: 201-689-8054

The call will also be available over the Internet and accessible at: https://www.webcaster4.com/Webcast/Page/2556/42132

Conference Call Replay Information

Toll Free: 877-481-4010 
International: 919-882-2331 
Replay Passcode: 42132

Webcast replay: https://www.webcaster4.com/Webcast/Page/2556/42132

About SBP-101

SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, suggesting potential complementary activity with an existing FDA-approved standard chemotherapy regimen. In data evaluated from clinical studies to date, SBP-101 has not shown exacerbation of bone marrow suppression or peripheral neuropathy, which can be chemotherapy-related adverse events. Recently observed serious visual adverse events are being evaluated and patients with a history of retinopathy or at risk of retinal detachment are excluded from SBP-101 studies. The safety data and PMI profile observed in the current Panbela sponsored clinical trial generally provides support for continued evaluation of SBP-101 in a randomized clinical trial.  For more information, please visit https://clinicaltrials.gov/ct2/show/NCT03412799 .

About Panbela

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company’s initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. is dedicated to treating patients with pancreatic cancer and exploring SBP-101’s potential for efficacy in combination with other agents in other cancer indications. Further information can be found at www.panbela.com . Panbela Therapeutics, Inc. common stock is listed on The Nasdaq Stock Market LLC under the symbol PBLA.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements,” including within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “believes,” “expect,” “intend,” “may,” “plan, ” and “will.” Examples of forward-looking statements include statements we make regarding the design and conduct of future clinical trials. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward- looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially and adversely from the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) our ability to obtain additional funding to complete a randomized clinical trial; (ii) progress and success of our Phase 1 clinical trial; (iii) the impact of the current COVID-19 pandemic on our ability to complete monitoring and reporting in our current clinical trial; (iv) our ability to demonstrate the safety and effectiveness of our SBP-101 product candidate (v) our ability to obtain regulatory approvals for our SBP-101 product candidate in the United States, the European Union or other international markets; (vi) the market acceptance and level of future sales of our SBP-101 product candidate; (vii) the cost and delays in product development that may result from changes in regulatory oversight applicable to our SBP-101 product candidate; (viii) the rate of progress in establishing reimbursement arrangements with third-party payors; (ix) the effect of competing technological and market developments; (x) the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims; and (xi) such other factors as discussed in Part I, Item 1A under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, any additional risks presented in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Any forward-looking statement made by us in this press release is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement or reasons why actual results would differ from those anticipated in any such forward-looking statement, whether written or oral, whether as a result of new information, future developments or otherwise.

Contact Information:

Investors: 
James Carbonara 
Hayden IR 
(646) 755-7412 
james@haydenir.com

Media: 
Tammy Groene 
Panbela Therapeutics, Inc. 
(952) 479-1196 
IR@panbela.com

FAQ

What are the details of Panbela Therapeutics' upcoming conference call?

Panbela Therapeutics' conference call is scheduled for August 11, 2021, at 4:30 PM ET, to discuss its second quarter results.

What is SBP-101 and its significance?

SBP-101 is a proprietary drug being developed by Panbela for treating metastatic pancreatic ductal adenocarcinoma, showing promise in clinical studies.

Have there been any adverse events related to SBP-101?

Yes, serious visual adverse events have been reported and are currently being evaluated.

How does SBP-101 compare to traditional chemotherapy?

SBP-101 has shown potential efficacy without exacerbating typical chemotherapy side effects such as bone marrow suppression.

Where can I find more information about Panbela Therapeutics?

Further information can be found on Panbela Therapeutics' official website.